15 March 2016

Positive results from RPL554 dose-finding study

VERONA PHARMA PLC - Positive results from RPL554 dose-finding study

Read more

15 March 2016

Verona Pharma reports positive results from RPL554 dose-finding study

Read more

10 February 2016

Grant of Share Options

VERONA PHARMA PLC - Grant of Share Options

Read more

21 January 2016

Director Dealing

Verona Pharma plc

Read more

11 January 2016

Directorate Change

VERONA PHARMA PLC - Directorate Change

Read more

3 December 2015

Director Dealing

VERONA PHARMA PLC - Director Dealing

Read more

1 December 2015

Holding(s) in Company

 

Read more

11 November 2015

RPL554 paper published in American Journal of Physiology

VERONA PHARMA PLC - RPL554 paper published in American Journal of Physiology

Read more

11 November 2015

Paper demonstrating that RPL554 enhances CTFR activation in cystic fibrosis airway epithelia published in American Journal of Physiology

Read more

5 November 2015

Patient enrolment completed in RPL554 PhIIa studies

VERONA PHARMA PLC - Patient enrolment completed in RPL554 PhIIa studies

Read more

Innovative Therapies for Respiratory Care

See the 2017 Verona Pharma corporate video 2017

Runtime: 04:05

Go

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us